Skip to content

Monosomy 7 Myelodysplasia And Leukemia Syndrome 2 C5436668

Published: July 22, 2026Updated: August 20, 2026

A condition caused by changes in the SAMD9L gene that increases risk of bone marrow failure and leukemia. Ongoing medical monitoring is important. Treatment may include stem cell transplantation.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Easy bruising or bleeding

!

Recurrent infections

Fatigue

(hematologic)

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Bone pain

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

High-Risk Hematologic Monitoring Protocol

Intensive surveillance schedule with frequent CBC, bone marrow evaluation, and molecular studies to detect early leukemic transformation in monosomy 7 syndrome.

monitoring
3

Curative Stem Cell Transplantation

Allogeneic bone marrow transplant from matched related or unrelated donor performed before leukemic transformation when possible for best outcomes.

surgical

Additional treatment options

Growth Factor Support

Granulocyte colony-stimulating factors and erythropoiesis-stimulating agents to support blood cell production and reduce transfusion dependence.

medication

Psychosocial Oncology Support

Counseling and mental health support addressing anxiety, depression, and adjustment issues faced by patients and families dealing with cancer predisposition syndromes.

psychological

Prophylactic Antimicrobial Therapy

Antibiotic and antiviral prophylaxis during periods of neutropenia or immunosuppression to prevent opportunistic infections.

medication

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Monosomy 7 Myelodysplasia And Leukemia Syndrome 2 C5436668?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Monosomy 7 Myelodysplasia And Leukemia Syndrome 2 C5436668. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy